TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Fortis Healthcare Ltd.

FORTIS on NSE · 19 Nov 2026

NIFTY 500 F&O

809.85 ▲ +2.05 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance

Guidance tracker

What FORTIS guided, and what came next

FiledWhat the filing saysNext results: profit YoYRevenueMove on the day
10 Nov 2026Fortis Healthcare filed the transcript of its Q2 and H1 FY'27 earnings call, held on November 06, 2026, on its unaudited results for the quarter and half year ended September 30, 2026. Management reported Q2 consolidated revenue of INR 2,735 crore, up 17.3% year on year, and Q2 operating EBITDA pre-ESOP of INR 663... NSE copy No results filed since
11 Aug 2026Fortis Healthcare filed the transcript of its Q1 FY27 earnings call held on August 7, 2026, on the unaudited results for the quarter ended June 30, 2026. Dr. Ashutosh Raghuvanshi (MD and CEO) said consolidated revenue was INR 2,545 crores, up 17.5% year-on-year, and consolidated operating EBITDA pre-ESOP was INR... NSE copy -3.0 %+17.3 %-6.5 %
29 May 2026Fortis Healthcare filed the transcript of its Q4 and FY26 earnings conference call, held May 25, 2026, to discuss audited results for the quarter and year ended March 31, 2026. Management said the Board recommended a dividend of INR1 per share (10% of face value), the fourth consecutive year, subject to shareholder... NSE copy +2.3 %+17.5 %+3.8 %
17 Nov 2025Fortis Healthcare filed the transcript of its Q2 FY26 earnings call held November 12, 2025, covering the quarter and half year ended September 30, 2025. Management (CEO Dr. Ashutosh Raghuvanshi) reported Q2 consolidated revenue of INR2,331 crores, up 17.3% year on year, and consolidated operating EBITDA of INR556... NSE copy -21.9 %+17.5 %-0.1 %
11 Aug 2025Fortis Healthcare filed the transcript of its Q1 FY26 earnings call held on August 7, 2025, covering results for the quarter ended June 30, 2025. Management (CEO Dr. Ashutosh Raghuvanshi) said consolidated revenue rose 16.6% to INR2,167 crores and operating EBITDA rose 43.2% to INR491 crores, a 22.6% margin versus... NSE copy +83.1 %+17.3 %-1.8 %
06 Aug 2025Fortis Healthcare filed its press release and earnings presentation for the quarter ended June 30, 2025 (Q1 FY26), under Regulation 30. Consolidated revenue was INR 2,167 Cr, up 16.6% YoY; operating EBITDA was INR 491 Cr with a 22.6% margin (vs 18.4% in Q1 FY25); PATMI was INR 260 Cr, up 56.8% YoY. Hospital... NSE copy +83.1 %+17.3 %-1.8 %
26 May 2025Fortis Healthcare filed the transcript of its Q4 FY25 and FY25 earnings call held on May 21, 2025, which discussed the audited results for the year ended March 31, 2025. Management said FY25 consolidated revenue was INR 7,783 crores (up 12.9%), consolidated operating EBITDA was INR 1,588 crores (20.4% margin), and... NSE copy +57.0 %+16.6 %+3.0 %
14 Feb 2025Fortis Healthcare filed the transcript of its Q3 FY25 earnings conference call held February 10, 2025, on the December 31, 2024 quarter results. Management reported Q3 consolidated revenue of INR 1,928 crores (up 14.8% YoY), consolidated operating EBITDA of INR 375 crores (19.4% margin vs 16.9%) and PAT before... NSE copy +57.0 %+16.6 %+3.0 %
14 Feb 2025Fortis Healthcare filed the transcript of its Q3 FY25 earnings call held on February 10, 2025, covering results for the quarter and period ended December 31, 2024. Management said consolidated revenue for Q3 FY25 was INR 1,928 crores, up 14.8%, with consolidated operating EBITDA up 32% to INR 375 crores (19.4%... NSE copy +57.0 %+16.6 %+3.0 %

Filings tagged as guidance, newest first (9 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
05 Nov 2026Legal or regulatoryFortis Healthcare Limited filed the outcome of its board meeting held on November 5, 2026, approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with a limited review report from the statutory auditor BSR & Co. LLP. Standalone revenue from... NSE copy
10 Sep 2026Legal or regulatoryFortis Healthcare filed the transcript of an investor/analyst conference call held on September 4, 2026, under Regulation 30, following a Delhi High Court order directing a forensic audit. Management (CEO Dr. Ashutosh Raghuvanshi, with IHH Group CFO Dilip Kadambi) said the order does not change the company's... NSE copy
11 Aug 2026Management changeFortis Healthcare filed the transcript of its Q1 FY27 earnings call held on August 7, 2026, on the unaudited results for the quarter ended June 30, 2026. Dr. Ashutosh Raghuvanshi (MD and CEO) said consolidated revenue was INR 2,545 crores, up 17.5% year-on-year, and consolidated operating EBITDA pre-ESOP was INR... NSE copy
06 Aug 2026Legal or regulatoryFortis Healthcare filed the outcome of its board meeting held August 6, 2026. The board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a limited review report from statutory auditor B S R & Co. LLP. The board appointed B S R & Co. LLP as Tax Auditors... NSE copy
08 Jul 2026Management changeFortis Healthcare's board on July 8, 2026 recommended, subject to shareholder approval, the re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director and Chief Executive Officer for two years effective March 19, 2027, not liable to retire by rotation. The current term of Dr. Raghuvanshi expires on March 18,... NSE copy
13 Feb 2026Legal or regulatory, Management changeFortis Healthcare filed the outcome of its board meeting held on February 13, 2026, which approved the unaudited standalone and consolidated financial results for the quarter and period ended December 31, 2025, along with the limited review report. The board approved the formulation of the Fortis Healthcare Limited... NSE copy
13 Feb 2026Legal or regulatoryFortis Healthcare filed the outcome of its board meeting held February 13, 2026, approving unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, with limited review report from the statutory auditor. The board approved formulation of the Fortis Healthcare... NSE copy
16 Jan 2026Legal or regulatoryFortis Healthcare filed a Regulation 30 disclosure on the composite scheme of merger by absorption of Fortis Emergency Services Ltd, Fortis Cancer Care Ltd, Fortis Health Management (East) Ltd and Birdie & Birdie Realtors Pvt Ltd into Fortis Hospitals Ltd, all wholly-owned subsidiaries. The scheme was approved by... NSE copy
06 Jan 2026Credit ratingFortis Healthcare Limited filed under Regulation 30 and 51 of the SEBI Listing Regulations, disclosing that CRISIL Ratings reaffirmed its ratings on the company's bank facilities and non-convertible debentures. Long-term rating reaffirmed at Crisil AA+/Stable and short-term rating at Crisil A1+; bank loan... NSE copy
11 Nov 2025Legal or regulatoryFortis Healthcare Limited's board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2025, on November 11, 2025, with a limited review report from BSR & Co. LLP. Standalone revenue from operations for the quarter ended September 30, 2025 was Rs 45,581 lacs,... NSE copy
11 Nov 2025Legal or regulatoryFortis Healthcare filed its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, approved at a board meeting held November 11, 2025, with a limited review report from BSR & Co. LLP. Standalone revenue from operations for the quarter ended September 30, 2025... NSE copy
01 Sep 2025Credit ratingFortis Healthcare Limited filed intimation under Regulation 30 of SEBI LODR regarding a credit rating by CRISIL Ratings. CRISIL upgraded the long-term bank facilities and non-convertible debentures to CRISIL AA+/Stable from CRISIL AA/Stable, and reaffirmed the short-term rating at CRISIL A1+. Rated amounts: bank... NSE copy
01 Sep 2025Legal or regulatoryFortis Healthcare filed the certified copy of the NCLT Chandigarh Bench order for a composite scheme of arrangement with the Registrar of Companies via Form INC-28 on September 1, 2025 at 05:55 P.M. (IST). The scheme involves International Hospital Limited, Fortis Hospitals Limited and Fortis Hospotel Limited, each... NSE copy
06 Aug 2025Management changeFortis Healthcare filed its press release and earnings presentation for the quarter ended June 30, 2025 (Q1 FY26), under Regulation 30. Consolidated revenue was INR 2,167 Cr, up 16.6% YoY; operating EBITDA was INR 491 Cr with a 22.6% margin (vs 18.4% in Q1 FY25); PATMI was INR 260 Cr, up 56.8% YoY. Hospital... NSE copy
06 Aug 2025Legal or regulatoryFortis Healthcare filed its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, approved by the Board at its meeting on August 06, 2025, along with the statutory auditor's limited review report. The filing does not state the revenue, profit or other figures in the text... NSE copy
06 Aug 2025Legal or regulatoryFortis Healthcare Limited filed the outcome of its board meeting held on August 06, 2025, including unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a limited review report from the statutory auditor. The board approved the appointment of B S R & Co. LLP, Chartered... NSE copy
31 Jul 2025Legal or regulatoryFortis Healthcare filed a Regulation 30 disclosure on the composite scheme of arrangement between International Hospital Limited, Fortis Hospitals Limited and Fortis Hospotel Limited, all wholly-owned subsidiaries of the company. The scheme was approved by NCLT New Delhi on May 9, 2025 and by NCLT Chandigarh on... NSE copy
20 May 2025Legal or regulatoryFortis Healthcare filed the outcome of its board meeting held May 20, 2025, approving audited standalone and consolidated results for the quarter and year ended March 31, 2025, with an unmodified audit opinion from statutory auditors B S R & Co. LLP. The board recommended a final dividend of ₹1 per equity share... NSE copy
07 Feb 2025Legal or regulatoryFortis Healthcare filed the outcome of its board meeting held February 7, 2025, which approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, along with the limited review report of the statutory auditors (BSR&Co. LLP). The board approved a... NSE copy
07 Feb 2025Legal or regulatoryFortis Healthcare filed the outcome of its board meeting held February 7, 2025, which approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with a limited review report from the statutory auditor (BSR&Co. LLP). The board approved a further... NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (23 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in